Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

MacroGenics Reports 2025 Financial Results and Highlights Upcoming Planned Data Disclosures

ROCKVILLE, Md., March 09, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on its recent corporate progress, reported financial results for the year ended December 31, 2025, and highlighted anticipated data disclosure timelines for its product pipeline.

MacroGenics Announces Pausing of Enrollment of New Study Participants in LINNET Trial

FDA has placed partial clinical hold on LINNET study of lorigerlimab in gynecologic cancer FDA has placed partial clinical hold on LINNET study of lorigerlimab in gynecologic cancer

MacroGenics to Participate in the 8th Annual Evercore Healthcare Conference

ROCKVILLE, MD, Nov. 25, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that Eric Risser, President and CEO of MacroGenics, will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on Thursday, December 4, at 7:55 am ET in Miami, FL. A webcast of the presentation may be accessed under "Events & Presentations" in the Investor Relations section of MacroGenics' website at http://ir.macrogenics.com/events.cfm.

MacroGenics Reports Third Quarter 2025 Financial Results and Provides Update on Corporate Progress

ROCKVILLE, Md., Nov. 12, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today reported financial results for the third quarter ended September 30, 2025, and provided an update on its recent corporate progress.